glp-1 drugs news The promises and pitfalls of New studies find that GLP-1

doi: 10.1136/ard-2023-224491 144 NemethTNagyGPapT

It situates individual peptides within the broader science of peptide therapy, teaches evidence interpretation and compliant sourcing, and is part of the larger Academy of Anti-Aging & Functional Medicine

10.1097/MOL.0000000000000278 91

According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on the specific agent and dose) Vomiting (524% of patients) Diarrhea (821% of patients) Constipation (1024% of patients) Abdominal pain or discomfort (514% of patients) These symptoms typically emerge during dose initiation or escalation and often diminish over several weeks as the body adapts

Their activation acutely increases renal blood flow and glomerular filtration rate via nitric oxide-mediated vasodilation [18]

There is more information about blood in the stool in the next section